Articles

Quick View: Lupin Achieves Three New Generic Approvals In The US Highlighting Continued Interest In Expanding Generics Portfolio

Pharmaceuticals / United States / Thu 18 Jan, 2024

The Latest: On January 14 2024, Lupin announced that it had received US FDA approval to market a generic version of propranolol hydrochloride extended-release capsules, used in the treatment of migraine and hypertension. The approval is significant as Lupin can offer a more affordable alternative to ANI Pharmaceuticals' Inderal LA extended

Read More

Brighter Export Outlook Will Buoy Zambian Growth In 2024

Country Risk / Zambia / Tue 16 Jan, 2024

Key View

  • We forecast that Zambian real GDP growth will accelerate from an estimated 3.5% in 2023 to 4.8% in 2024.
  • While improving investor sentiment and higher copper prices will support fixed investment growth, elevated inflation and tight credit conditions will weigh on private consumption.
  • We forecast that in 2025, economic growth will
Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.